These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 10861472

  • 21. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 22. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
    Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, Muller WJ.
    Mol Cell Biol; 2007 Sep 15; 27(18):6361-71. PubMed ID: 17636013
    [Abstract] [Full Text] [Related]

  • 23. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M, Yao J, Yu D.
    Cancer Res; 1997 Mar 15; 57(6):1199-205. PubMed ID: 9067293
    [Abstract] [Full Text] [Related]

  • 24. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha.
    Ethier SP, Langton BC, Dilts CA.
    Mol Carcinog; 1996 Feb 15; 15(2):134-43. PubMed ID: 8599580
    [Abstract] [Full Text] [Related]

  • 25. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.
    Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI.
    Cell; 1985 Jul 15; 41(3):697-706. PubMed ID: 2860972
    [Abstract] [Full Text] [Related]

  • 26. The extracellular domain of p185(c-neu) induces density-dependent inhibition of cell growth in malignant mesothelioma cells and reduces growth of mesothelioma in vivo.
    Yoneda T, Kumagai T, Nagatomo I, Furukawa M, Yamane H, Hoshino S, Mori M, Takeda Y, Horai T, Nishida S, Watanabe D, Kijima T, Yoshida M, Osaki T, Tachibana I, Greene MI, Kawase I.
    DNA Cell Biol; 2006 Sep 15; 25(9):530-40. PubMed ID: 16989576
    [Abstract] [Full Text] [Related]

  • 27. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 28. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
    Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E.
    Cancer Res; 2007 Sep 15; 67(18):8671-81. PubMed ID: 17875707
    [Abstract] [Full Text] [Related]

  • 29. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM.
    Cancer Res; 2000 Jul 01; 60(13):3569-76. PubMed ID: 10910070
    [Abstract] [Full Text] [Related]

  • 30. Cyclin D1 is necessary but not sufficient for anchorage-independent growth of rat mammary tumor cells and is associated with resistance of the Copenhagen rat to mammary carcinogenesis.
    Li YJ, Song R, Korkola JE, Archer MC, Ben-David Y.
    Oncogene; 2003 May 29; 22(22):3452-62. PubMed ID: 12776197
    [Abstract] [Full Text] [Related]

  • 31. Fibronectin fibrils and growth factors stimulate anchorage-independent growth of a murine mammary carcinoma.
    Saulnier R, Bhardwaj B, Klassen J, Leopold D, Rahimi N, Tremblay E, Mosher D, Elliott B.
    Exp Cell Res; 1996 Feb 01; 222(2):360-9. PubMed ID: 8598224
    [Abstract] [Full Text] [Related]

  • 32. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model.
    Ménard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI, Balsari A.
    Cancer Res; 2000 Jan 15; 60(2):273-5. PubMed ID: 10667575
    [Abstract] [Full Text] [Related]

  • 33. Over-expression of erbB-2/neu is paralleled by inhibition of mouse-mammary-epithelial-cell differentiation and developmental apoptosis.
    Lazar H, Baltzer A, Gimmi C, Marti A, Jaggi R.
    Int J Cancer; 2000 Feb 15; 85(4):578-83. PubMed ID: 10699933
    [Abstract] [Full Text] [Related]

  • 34. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 15; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 35. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
    Lachman LB, Rao XM, Kremer RH, Ozpolat B, Kiriakova G, Price JE.
    Cancer Gene Ther; 2001 Apr 15; 8(4):259-68. PubMed ID: 11393278
    [Abstract] [Full Text] [Related]

  • 36. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice.
    Kurt RA, Whitaker R, Baher A, Seung S, Urba WJ.
    Int J Cancer; 2000 Sep 01; 87(5):688-94. PubMed ID: 10925363
    [Abstract] [Full Text] [Related]

  • 37. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
    Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ.
    Proc Natl Acad Sci U S A; 1992 Nov 15; 89(22):10578-82. PubMed ID: 1359541
    [Abstract] [Full Text] [Related]

  • 38. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells.
    Tsai CM, Levitzki A, Wu LH, Chang KT, Cheng CC, Gazit A, Perng RP.
    Cancer Res; 1996 Mar 01; 56(5):1068-74. PubMed ID: 8640763
    [Abstract] [Full Text] [Related]

  • 39. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
    Xing X, Matin A, Yu D, Xia W, Sorgi F, Huang L, Hung MC.
    Cancer Gene Ther; 1996 Mar 01; 3(3):168-74. PubMed ID: 8725881
    [Abstract] [Full Text] [Related]

  • 40. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun 01; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.